ZymoGenetics, Inc. Shares Benefit From Human Genome Sciences, Inc. Trial Success Reported Monday, July 20

Seattle Times -- ZymoGenetics shares leapt 19.5 percent Monday after the reported success of a lupus drug from Human Genome Sciences raised hopes for a similar therapeutic originated by the Seattle company.